Oral Minoxidil for Hair Loss: Prescribing Information and What Studies Report

PrescribedRX is a telehealth platform; prescriptions are written by licensed clinicians and filled by licensed partner pharmacies.

Short answer: Oral minoxidil tablets are prescription drugs for high blood pressure that is hard to control, and using them as a hair loss treatment is off-label. The minoxidil tablets prescribing information says using the tablets “to promote hair growth is not an approved indication,” and it carries a boxed warning (minoxidil tablets prescribing information). In a 24-week trial, oral minoxidil 5 mg “did not demonstrate superiority” over topical 5% (Penha et al., 2024), and a 2025 meta-analysis of 4 trials found no difference in hair density between the two (Sobral et al., 2025).

This page covers what the prescribing information says, then what each hair loss study measured. Side effects and low-dose safety data have their own page: oral minoxidil side effects and the boxed warning in context.

What is oral minoxidil prescribed for?

The minoxidil tablets prescribing information limits use to hypertension “that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs.” A separate section titled “Unapproved Use” states: “Use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication” (minoxidil tablets prescribing information). The tablets come in 2.5 mg and 10 mg strengths and are prescription only.

What does off-label mean?

Off-label use means a medicine is prescribed for a condition, form or dose that its prescribing information does not describe. Hair loss is not among the uses the minoxidil tablets prescribing information lists, so oral minoxidil for hair loss is prescribed off-label.

Prescribing information point	What it says	Source
Approved indication	Hypertension not manageable with a diuretic plus two other blood pressure drugs	Prescribing information
Hair growth	“Not an approved indication”	Prescribing information, Unapproved Use
Boxed warning	Pericardial effusion, possible tamponade, worsening angina	Prescribing information
Tablet strengths	2.5 mg and 10 mg	Prescribing information
Status	Prescription only	Prescribing information

What does the boxed warning say?

The boxed warning, the most prominent warning in the minoxidil tablets prescribing information, reads in part: minoxidil “may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated.” It says minoxidil “should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents,” and that it is usually given with a beta-blocker and a diuretic (minoxidil tablets prescribing information).

That warning was written for blood pressure treatment. What has been reported at the lower doses used in hair loss studies is covered on our oral minoxidil side effects page.

What do studies of oral minoxidil for hair loss report?

These studies differ in design, so the rows are not directly comparable.

Study	Design	Who	Dose and length	What was reported
Penha 2024	Double-blind randomized trial, one clinic in Brazil	90 men aged 18 to 55 enrolled, 68 completed	Oral 5 mg daily vs topical 5% twice daily, 24 weeks	Oral “did not demonstrate superiority” over topical; ahead on vertex photos only
Sobral 2025	Meta-analysis of randomized trials	4 trials, 279 patients	Oral vs topical, 24 to 39 weeks	No difference in hair density or hair diameter; more body hair growth with oral
Gupta 2022	Network meta-analysis	23 studies of men	Pooled doses and routes, 24 and 48 weeks	Largest terminal hair count gain at 24 weeks with 5 mg/day minoxidil
Liu 2025	Single-arm meta-analysis	27 studies, 2,933 patients, all alopecia types	Various doses	35% significant improvement, 47% improvement, 26% stable; adverse events 27%
Vañó-Galván 2021	Retrospective safety cohort, no control group	1,404 patients (943 women, 461 men)	Low doses, at least 3 months	Safety outcomes only; see our side effects page

Penha 2024: oral vs topical in one trial

Men with pattern hair loss were randomized to oral minoxidil 5 mg daily plus a placebo solution, or topical 5% minoxidil twice daily plus a placebo pill, for 24 weeks. On the vertex, the difference in terminal hair density between groups was 23.4 hairs per square centimeter, which was not statistically significant (95% CI, -0.3 to 43.0; P = .09). On photos, oral was ahead on the vertex (24%; P = .04) but not on the front of the scalp. The authors concluded that oral minoxidil “did not demonstrate superiority” over topical. In the oral group, 49% reported unwanted body hair growth and 14% headache (Penha et al., 2024).

Sobral 2025: four trials pooled

This meta-analysis pooled 4 randomized trials with 279 patients and follow-up of 24 to 39 weeks. It found no difference between oral and topical minoxidil in hair density (SMD 0.02; P = .88) or hair diameter (P = .34). Hypertrichosis, meaning unwanted hair growth elsewhere on the body, was about twice as common with oral minoxidil (risk ratio 2.01; P = .01). Low blood pressure did not differ significantly between groups (Sobral et al., 2025).

Gupta 2022: a network meta-analysis

This analysis combined 23 studies of minoxidil, finasteride and dutasteride in men. It reported that the greatest increase in terminal (thick) hair count at 24 weeks was with 5 mg a day of oral minoxidil, which was 10.4 hairs per square centimeter ahead of finasteride 1 mg. At 48 weeks, the greatest terminal hair gain was with finasteride 1 mg (Gupta et al., 2022). A network meta-analysis compares treatments across separate studies; it is not a head-to-head trial, and the authors note that head-to-head data are still accumulating.

Liu 2025: a broader pooled estimate

This review pooled 27 studies with 2,933 patients across types of hair loss, not only male pattern hair loss. Pooled rates were 35% for significant improvement, 47% for improvement and 26% for stable symptoms, with adverse events reported in 27%. The authors wrote that patients “may derive benefits from oral minoxidil, particularly at doses exceeding 1 mg,” and that “additional research or data is essential to definitively establish its efficacy and safety” (Liu et al., 2025). A single-arm analysis has no comparison group.

For how results unfold over time with minoxidil generally, see our minoxidil results timeline.

What doses were used in studies?

The tablets on the US market come in 2.5 mg and 10 mg strengths (minoxidil tablets prescribing information). The hair loss doses reported in the studies here are:

• 5 mg once daily in the Penha 2024 trial (Penha et al., 2024).
• 5 mg a day as the top-ranked arm for terminal hair at 24 weeks in the Gupta 2022 analysis (Gupta et al., 2022).
• “Doses exceeding 1 mg” in the Liu 2025 authors’ conclusion (Liu et al., 2025).

These are study facts, not instructions. The prescribing information gives no hair loss dose. Your provider sets the dose.

Is oral minoxidil better than topical?

On hair density, the cited trials did not find it superior. Penha 2024 found oral 5 mg “did not demonstrate superiority” over topical 5% at 24 weeks, and Sobral 2025 found no difference in hair density or diameter across 4 trials. Sobral 2025 reported unwanted body hair growth about twice as often with the oral form (Penha et al., 2024; Sobral et al., 2025). For minoxidil alongside finasteride, see minoxidil vs finasteride and our finasteride hair loss guide.

What does the tablet prescribing information say about body hair?

The minoxidil tablets prescribing information reports that elongation, thickening and darkening of fine body hair “are seen in about 80% of patients taking minoxidil tablets” and that this “develops within 3 to 6 weeks after starting therapy,” usually first on the temples, between the eyebrows or the upper cheeks. On stopping, “new hair growth stops, but 1 to 6 months may be required for restoration to pretreatment appearance” (minoxidil tablets prescribing information). Those figures come from blood pressure patients, not low-dose hair loss use.

When should you talk to a doctor?

Talk to a licensed provider before taking oral minoxidil, especially if you have a heart condition or take other medicines. Our oral minoxidil side effects page lists what low-dose studies reported, and our hair loss treatment safety information page has general safety information. In an emergency, call 911.

Where does PrescribedRX fit?

PrescribedRX does not offer minoxidil tablets on their own. The hair loss treatment offered through PrescribedRX is Hair We Grow, listed on its product page as “Finasteride + minoxidil · One daily capsule.” It is compounded. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. The studies above tested minoxidil alone, not this combination capsule, so their results do not apply to it. The product page does not list the minoxidil strength.

A licensed provider decides whether it is appropriate for you, and your provider sets the dose. Plans are self-pay, and availability varies by state. Prices as shown on prescribedrx.com in October 2026 (see what every PrescribedRX treatment costs):

Plan	Price as displayed
Hair We Grow, 3 months	3 month plan $220 · $73/mo · Billed every 3 months. Cancel anytime.
Hair We Grow, monthly	Monthly plan $90 a month

Frequently asked questions

Is oral minoxidil used for hair loss?

It is prescribed off-label. Minoxidil tablets are prescribed for hypertension that is not controlled by a diuretic plus two other blood pressure drugs, and the minoxidil tablets prescribing information says using the tablets to promote hair growth “is not an approved indication.” Prescribing it for hair loss is off-label.

What is a minoxidil 2.5 mg tablet?

It is one of the two strengths of generic prescription minoxidil tablets, 2.5 mg and 10 mg, listed in the minoxidil tablets prescribing information, which describes them as blood pressure tablets. Any hair loss use of these tablets is off-label, and your provider sets the dose.

What dose of oral minoxidil is used for hair loss?

The minoxidil tablets prescribing information gives no hair loss dose. Penha 2024 tested 5 mg daily, Gupta 2022 reported the 5 mg a day arm ranked highest for terminal hair at 24 weeks, and Liu 2025 authors referred to “doses exceeding 1 mg.” Your provider sets the dose.

Does oral minoxidil cause body hair growth?

The minoxidil tablets prescribing information reports thicker, darker body hair in about 80% of blood pressure patients, within 3 to 6 weeks. In the Penha 2024 hair loss trial, 49% of the oral 5 mg group reported unwanted body hair growth, and Sobral 2025 found it about twice as common with oral as with topical minoxidil.

Questions about oral minoxidil? Talk to a licensed provider

A licensed provider can review your hair loss, your health history and the options available in your state, and decide whether treatment is appropriate for you. Explore prescription hair loss treatment online, or compare options in hair loss treatments ranked by evidence.

Hair We Grow (finasteride and minoxidil in one daily capsule; compounded): 3 month plan $220 · $73/mo · Billed every 3 months. Cancel anytime. A licensed provider decides whether it is appropriate for you.

Related reading: Minoxidil for Beard Growth: What Studies Report

Sources

1. DailyMed, National Library of Medicine. Minoxidil tablets prescribing information (American Health Packaging). dailymed.nlm.nih.gov. Accessed Oct 2026.
2. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600-605. PubMed. Accessed Oct 2026.
3. Sobral MVS, Moreira JLML, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol. 2025;64(3):479-484. PubMed. Accessed Oct 2026.
4. Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022;158(3):266-274. PubMed. Accessed Oct 2026.
5. Liu C, et al. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Front Pharmacol. 2025;16:1556705. PubMed. Accessed Oct 2026.
6. Vañó-Galván S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. PubMed. Accessed Oct 2026.

This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.